|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alteon Inc., of Parsippany, N.J., said one of its collaborators at the Baker Heart Research Institute in Melbourne, Australia, was awarded a grant from the Juvenile Diabetes Research Foundation to help fund a multinational Phase II study of alagebrium's effect on renal function in Type I diabetics and microalbuminuria. An A.G.E. crosslink breaker, Alteon's lead compound will be tested for its ability to reverse kidney damage caused by diabetes, and to reverse the protein excretion which is characteristic of diabetic nephropathy. The study will include 80 patients who will receive placebo and an ACE inhibitor during an eight-week, single-blind, run-in period. This will be ...
Related newspaper, magazine, and journal articles:
|